

WORKSHEET:	Regulatory Rev	/iew
DOC #	REV DATE	PAGE
HRP-420	05/19/2023	1 of 2

This worksheet is used when <Regulatory Reviewers> conduct <Regulatory Review>

1.		ems that apply	
1.1	Regulated by:		
	DHS-Department of Homeland Security	□ HHS-Department of Health and Human Services (via FWA)	
1.2	□ DOD-Department of Defense	HHS-Department of Health and Human Services (via funding	
	ED-Department of Education	Other Common Rule Agency	
	FDA-Food and Drug Administration	□ <2018 Requirements>	
1.3	Requires compliance with ICH-GCP		
1.4	□ Additional local, state, or international laws apply.		
2.	Determinations		
2.1	Waiver of Consent HHS (HRP-300)		
2.2	Waiver of Consent Emergency Research (HRP-301)		
2.3	□ Waiver of Consent Leftover Specimens (HRP-302)		
2.4	Waiver of Documentation of Consent (HRP-303)		
2.5	Waiver of Assent (HRP-304)		
2.6	Pregnant Women (HRP-305)		
2.7	Neonates of Uncertain Viability (HRP-306)		
2.8	Nonviable Neonates (HRP-307)		
2.9	Prisoners (HRP-308)		
2.10	Unexpected Incarceration (HRP-309)		
2.11	Children (HRP 310)		
2.12	U Wards (HRP-311)		
2.13	□ Scientific and Scholarly Review (HRP-401)		
2.14	□ Advertisements (HRP-402)		
2.15	□ Payments (HRP-403)		
2.16	Short Form (HRP-404)		
2.17	□ Additional Criteria DOD (HRP-405)		
2.18	□ Additional Criteria ED (HRP-407)		
2.19	□ Additional Criteria International (HRP-410)		
2.20	□ Adults Lacking Capacity (HRP-414)		
3.	Drugs		
3.1	□ Evaluate all drugs whose use is specified by the protocol	(See "WORKSHEET: Drugs (HRP-326)" for definition of device)	
3.2	□ For approved drugs ensure that a package insert is available	able to IRB members	
3.3	Determine IND status and contingencies (See "WORKSH	IEET: Drugs (HRP-425)")	
3.4	Procedures to control IND drugs are adequate to prevent	use in individuals who are not subjects	
3.5	□ Procedures are in place to comply with sponsor req	uirements when an investigator holds the IND	



WORKSHEET:	Regulatory Rev	/iew
DOC #	REV DATE	PAGE
HRP-420	05/19/2023	2 of 2

-	
4.	
4.1	Evaluate all devices being evaluated for safety or effectiveness (See "CHECKLIST: Devices (HRP-326)" for definition of device)
4.2	Ensure that a PMA, 510(k), HDE approval or copy of Class I exemption category for approved devices is available to IRB
	members
4.3	Determine IDE status and contingencies (See CHECKLIST: Devices (HRP-326)")
4.4	Procedures to control IDE devices are adequate to prevent use in individuals who are not subjects
4.5	Procedures are in place to comply with sponsor requirements when an investigator holds the IDE
5.	Check
5.1	The [Organization's] policy allows the research
5.2	The submission is complete
5.3	□ Investigators and research staff are up to date on training
5.4	□ Site agreements are in place
5.5	Investigator agreements are in place
5.6	FWA is present for federally funded research
5.7	□ An agency-specific assurance or assurance addendum is present when required (e.g., DOD)
5.8	Financial declarations have been made
5.9	A management plan is in place for any positive financial declaration
5.10	The [Organization] has no financial interest in the research
5.11	□ The description of <legally authorized="" representative=""> is consistent with laws of the jurisdiction in which the research is</legally>
	conducted
5.12	□ The description of <children> is consistent with laws of the jurisdiction in which the research is conducted</children>
5.13	□ The description of <guardians> is consistent with laws of the jurisdiction in which the research is conducted</guardians>
5.14	□ HIPAA authorization requirements are not needed or are met (See "WORKSHEET: HIPAA Authorization (HRP-427)")
5.15	□ HIPAA wavier of authorization requirements are not needed or are met (See "WORKSHEET: HIPAA Waiver of Authorization
	(HRP-428)")
6.	Notes